LabCorp/$LH
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About LabCorp
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from uncomplicated routine blood and urine screens to complex oncology and genomic testing.
- Ticker
- $LH
- Sector
- Health
- Primary listing
- NYSE
- Employees
- -
- Headquarters
- Burlington, United States
- Website
- www.labcorp.com
LabCorp Metrics
BasicAdvanced
$27B
27.42
$12.08
0.84
$2.88
0.87%
Price and volume
Market cap
$27B
Beta
0.84
52-week high
$341.80
52-week low
$244.52
Average daily volume
734K
Dividend rate
$2.88
Financial strength
Current ratio
1.796
Quick ratio
1.246
Long term debt to equity
0.77
Total debt to equity
0.785
Dividend payout ratio (TTM)
23.86%
Interest coverage (TTM)
7.12%
Profitability
EBITDA (TTM)
2,319.8
Gross margin (TTM)
28.88%
Net profit margin (TTM)
6.99%
Operating margin (TTM)
11.28%
Effective tax rate (TTM)
18.66%
Management effectiveness
Return on assets (TTM)
5.53%
Return on equity (TTM)
11.73%
Valuation
Price to earnings (TTM)
27.423
Price to revenue (TTM)
1.903
Price to book
3.11
Price to tangible book (TTM)
-12.75
Price to free cash flow (TTM)
23.637
Free cash flow yield (TTM)
4.23%
Free cash flow per share (TTM)
14.011
Dividend yield (TTM)
0.87%
Forward dividend yield
0.87%
Growth
Revenue change (TTM)
6.41%
Earnings per share change (TTM)
33.20%
3-year revenue growth (CAGR)
6.53%
10-year revenue growth (CAGR)
4.55%
3-year earnings per share growth (CAGR)
9.15%
10-year earnings per share growth (CAGR)
7.04%
What the Analysts think about LabCorp
Analyst ratings (Buy, Hold, Sell) for LabCorp stock.
Analyst projections of the future price of LabCorp stock.
Bulls say / Bears say
Third-quarter revenue rose 6.9%, organic growth was 5.5% and adjusted EPS grew 14.5%. Labcorp raised its 2026 revenue-growth and adjusted-EPS guidance, signalling continued momentum. (PR Newswire)
Biopharma Laboratory Services grew revenue 8.5%, with 9.6% organic growth, and ended the quarter with an $8.92 billion backlog. That provides a sizeable base of contracted work to support future revenue. (PR Newswire)
Specialty testing is taking a larger share of Diagnostics revenue, and Labcorp continues to add differentiated tests, including an FDA-approved melanoma companion diagnostic and an Alzheimer’s blood test. These offerings could help it capture growth in higher-value testing. (PR Newswire, Labcorp)
Proposed Medicare laboratory fee rates could weigh on reimbursement from 2027; management has cited an estimated $125 million impact in that year. The final effects remain uncertain, leaving a material policy risk to earnings. (U.S. Securities and Exchange Commission, Investing.com)
Despite higher revenue, reported operating margin fell to 10.6% from 11.1% year on year, while adjustments to operating income rose to $167.9 million from $116.7 million. This gap raises a question about how much of the improvement in adjusted earnings translates into reported operating profit. (PR Newswire)
Labcorp agreed to pay $14.5 million to resolve allegations that it billed Medicare for medically unnecessary urine drug tests. The settlement highlights compliance risk in a business that depends on public-payer reimbursement. (U.S. Department of Justice)
Data summarised monthly by Lightyear AI. Last updated on 28 Oct 2026.
LabCorp Financial Performance
Revenues and expenses
LabCorp Earnings Performance
Company profitability
Upcoming events
LabCorp News
AllArticlesVideos
Funds containing LabCorp
AllUSDEURGBP
Fund name | Fund size | $LH weighting |
|---|---|---|
SPDR S&P 500 Low Volatility£USLV | $113M | 0.89% |
SPDR S&P 500 Low Volatility$LOWV | $113M | 0.89% |
Invesco S&P 500 Low Volatility£SPLG | $143M | 0.88% |
iShares Ageing Population$AGED | $953M | 0.60% |
iShares Ageing Population£AGES | $953M | 0.60% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.